Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6566956 | 0.84 | PARP1 (0.47) | PARP1MEN1KMT2ABCAT2KDM4E | |
| SCHEMBL6075761 | 0.82 | KDM4E (0.41) | PARP1MEN1KMT2ABCAT2KDM4E | |
| SCHEMBL619877 | 0.81 | ALDH1A1 (0.52) | PARP1MEN1KMT2ABCAT2KDM4E | |
| SCHEMBL8652707 | 0.81 | HMGB1 (0.54) | PARP1MEN1KMT2ABCAT2KDM4E | |
| SCHEMBL466296 | 0.80 | KDM4E (0.54) | PARP1BCAT2KDM4EHPGDALDH1A1 | |
| SCHEMBL5545298 | 0.80 | PARP1 (0.46) | PARP1MEN1KMT2ABCAT2KDM4E | |
| SCHEMBL7325664 | 0.80 | HMGB1 (0.49) | PARP1MEN1KMT2ABCAT2KDM4E | |
| SCHEMBL3483399 | 0.79 | KDM4E (0.38) | PARP1MEN1KMT2ABCAT2KDM4E | |
| SCHEMBL1063004 | 0.79 | BID (0.41) | PARP1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL5545065 | 0.78 | ALDH1A1 (0.47) | MEN1KMT2AHPGDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7186538-A | — | — | None | — | — | JP | disclosed |
| US-20250340507-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARM INNC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9522872-B2 | Methods for synthesizing substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2176216-B1 | METHODS FOR SYNTHESIZING 9-SUBSTITUTED MINOCYCLINE | PARATEK PHARM INNC (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2192111-A2 | Methods for synthesizing substituted tetracycline compounds | Paratek Pharmaceuticals, Inc. (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-2176216-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | Paratek Pharmaceuticals, Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20090156842-A1 | Methods for synthesizing substituted tetracycline compounds | PARATEK PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2009009042-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| EP-1347968-A1 | LFA-1 ANTAGONIST COMPOUNDS | GENENTECH, INC. (US) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002059114-A9 | LFA-1 ANTAGONIST COMPOUNDS | GENENTECH INC (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002059114-A1 | LFA-1 ANTAGONIST COMPOUNDS | GENENTECH, INC. (US) | 2002-08-01 | — | — | WO | disclosed |
| JP-H07186538-A | OPTICAL RECORDING MATERIAL | TOYO INK MFG CO LTD | 1995-07-25 | — | — | JP | disclosed |
| EP-0073826-A1 | RAPID SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES USING PHOSPHORUS OXYCHLORIDE ACTIVATION | BIORESEARCH INC. (US) | 1983-03-16 | — | — | EP | disclosed |
| WO-1982003079-A1 | RAPID SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES USING PHOSPHORUS OXYCHLORIDE ACTIVATION | BIORESEARCH INC (US) | 1982-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156842-A1 | Methods for synthesizing substituted tetracycline compounds | TET3, TET1, DHFR | PARP1 2378/4885MEN1 2384/4885KMT2A 1153/4885 |
| US-20250340507-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | TET3, TET1, DHFR | PARP1 2378/4885MEN1 2384/4885KMT2A 1153/4885 |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | TET3, TET1, DHFR | PARP1 2378/4885MEN1 2384/4885KMT2A 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.